RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Cabaletta Bio Stock

Cabaletta Bio Net Income 2024

Cabaletta Bio Net Income

-112.11 M USD

Ticker

CABA

ISIN

US12674W1099

WKN

A2PTTB

In 2024, Cabaletta Bio's profit amounted to -112.11 M USD, a 65.65% increase from the -67.68 M USD profit recorded in the previous year.

The Cabaletta Bio Net Income history

YEARNET INCOME (undefined USD)
2029e155.96
2028e51.98
2027e-46.67
2026e-123.41
2025e-120.19
2024e-112.11
2023-67.68
2022-52.98
2021-46.29
2020-33.34
2019-22.27
2018-12.2
2017-0.25

Cabaletta Bio Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Cabaletta Bio, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Cabaletta Bio from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Cabaletta Bio’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Cabaletta Bio. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Cabaletta Bio’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Cabaletta Bio’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Cabaletta Bio’s growth potential.

Cabaletta Bio Revenue, EBIT and net profit per share

DateCabaletta Bio RevenueCabaletta Bio EBITCabaletta Bio Net Income
2029e520.18 M undefined0 undefined155.96 M undefined
2028e253.51 M undefined-62.63 M undefined51.98 M undefined
2027e71.96 M undefined-147.88 M undefined-46.67 M undefined
2026e2.19 M undefined-159.02 M undefined-123.41 M undefined
2025e0 undefined-129.99 M undefined-120.19 M undefined
2024e0 undefined-117.42 M undefined-112.11 M undefined
20230 undefined-74.66 M undefined-67.68 M undefined
20220 undefined-54.14 M undefined-52.98 M undefined
20210 undefined-46.31 M undefined-46.29 M undefined
20200 undefined-33.83 M undefined-33.34 M undefined
20190 undefined-18.68 M undefined-22.27 M undefined
20180 undefined-6.19 M undefined-12.2 M undefined
20170 undefined-250,000 undefined-250,000 undefined

Cabaletta Bio stock margins

The Cabaletta Bio margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Cabaletta Bio. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Cabaletta Bio.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Cabaletta Bio's sales revenue. A higher gross margin percentage indicates that the Cabaletta Bio retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Cabaletta Bio's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Cabaletta Bio's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Cabaletta Bio's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Cabaletta Bio. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Cabaletta Bio's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Cabaletta Bio Margin History

Cabaletta Bio Gross marginCabaletta Bio Profit marginCabaletta Bio EBIT marginCabaletta Bio Profit margin
2029e0 %0 %29.98 %
2028e0 %-24.7 %20.51 %
2027e0 %-205.5 %-64.86 %
2026e0 %-7,274.29 %-5,645.49 %
2025e0 %0 %0 %
2024e0 %0 %0 %
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %

Cabaletta Bio Aktienanalyse

What does Cabaletta Bio do?

Cabaletta Bio Inc is a biotech company founded in 2017, based in Philadelphia, Pennsylvania. The founders of the company are Michael Milone and Aimee Payne, both renowned experts in immunology. The business model of Cabaletta Bio Inc is to treat rare diseases using T-cell therapies. T-cell therapy is a form of immunotherapy where the patient's own T-cells, which have been taken from their blood, are genetically modified and then reintroduced to the patient. This process is intended to enable the patient's T-cells to recognize and fight specific diseased cells. Cabaletta Bio Inc focuses on developing therapies for rare autoimmune diseases and difficult-to-treat cancers. The company specializes in the development of CAR-T cell therapies (CAR-T stands for Chimeric Antigen Receptor) that enable the patient's T-cells to attack specific tumor or autoimmune cells in the body. Novel CAR-T cell technologies have been developed to allow the T-cells to recognize disease-specific antigens on cell surfaces. This way, the T-cells can selectively target and destroy diseased cells. Cabaletta Bio Inc is working on various areas of T-cell therapy development. The first area involves developing therapies for rare autoimmune diseases such as systemic scleroderma, Juvenile syndrome, or pemphigus vulgaris. The company has initiated clinical trials and collaborates with other research institutions and companies to advance the development of CAR-T cell therapies. Another area of focus for Cabaletta Bio Inc is treating cancers that are difficult to treat and lack therapeutic options, such as leukemia, solid tumors, or sarcomas. Identifying and targeting specific cells for these types of cancers is particularly challenging. Therefore, the company is actively working to develop novel CAR-T cell technologies that enable the T-cells to recognize and combat diseased cells. Currently, Cabaletta Bio Inc does not offer any commercial products as it is still in the phase of clinical research and development. However, the company aims to advance the development of T-cell therapies and make its technology accessible to patients with rare and difficult-to-treat diseases. Overall, Cabaletta Bio Inc has received recognition and support from leading scientists and organizations in recent years. The company has received several awards and accolades for its work, including the New Frontier Award from the National Organization for Rare Disorders (NORD) and the Fast Track Award from the US Food and Drug Administration (FDA). Cabaletta Bio Inc collaborates closely with various research institutions, universities, and companies to improve its technology and develop new therapies. In summary, Cabaletta Bio Inc is an emerging biotech company specializing in the development of T-cell therapies. The company aims to treat rare and difficult-to-treat diseases and make its technology accessible to patients. Although the company currently does not offer commercial products, it has received recognition and support from leading scientists and organizations in recent years and collaborates closely with various research institutions, universities, and companies to improve its technology and develop new therapies. Cabaletta Bio ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Cabaletta Bio's Profit Margins

The profit margins of Cabaletta Bio represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Cabaletta Bio's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Cabaletta Bio's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Cabaletta Bio's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Cabaletta Bio’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Cabaletta Bio stock

How much profit has Cabaletta Bio made this year?

Cabaletta Bio has made -112.11 M USD this year.

How has the profit developed compared to last year?

The profit has increased by 65.65% compared to last year increased

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Cabaletta Bio publish its earnings?

Cabaletta Bio publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Cabaletta Bio?

The profits of Cabaletta Bio are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Cabaletta Bio?

You can learn more about the earnings of Cabaletta Bio by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Cabaletta Bio pay?

Over the past 12 months, Cabaletta Bio paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Cabaletta Bio is expected to pay a dividend of 0 USD.

What is the dividend yield of Cabaletta Bio?

The current dividend yield of Cabaletta Bio is .

When does Cabaletta Bio pay dividends?

Cabaletta Bio pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Cabaletta Bio?

Cabaletta Bio paid dividends every year for the past 0 years.

What is the dividend of Cabaletta Bio?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Cabaletta Bio located?

Cabaletta Bio is assigned to the 'Health' sector.

Wann musste ich die Aktien von Cabaletta Bio kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Cabaletta Bio from 9/14/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/14/2024.

When did Cabaletta Bio pay the last dividend?

The last dividend was paid out on 9/14/2024.

What was the dividend of Cabaletta Bio in the year 2023?

In the year 2023, Cabaletta Bio distributed 0 USD as dividends.

In which currency does Cabaletta Bio pay out the dividend?

The dividends of Cabaletta Bio are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Cabaletta Bio

Our stock analysis for Cabaletta Bio Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cabaletta Bio Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.